AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

ACIU has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of AC Immune in a research note on Thursday, January 24th. UBS Group began coverage on AC Immune in a research report on Friday, January 4th. They set a “buy” rating and a $16.00 price target for the company. BidaskClub raised AC Immune from a “hold” rating to a “buy” rating in a research report on Wednesday, November 21st. Finally, Leerink Swann assumed coverage on AC Immune in a research note on Monday, November 12th. They set an “outperform” rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $12.10.

ACIU opened at $3.91 on Tuesday. The stock has a market capitalization of $258.18 million, a P/E ratio of -13.03 and a beta of -0.09. AC Immune has a fifty-two week low of $3.25 and a fifty-two week high of $17.40.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. The business had revenue of $2.34 million for the quarter, compared to analyst estimates of $1.71 million. Analysts expect that AC Immune will post -0.01 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of ACIU. State of New Jersey Common Pension Fund D purchased a new stake in shares of AC Immune during the third quarter worth $626,000. JPMorgan Chase & Co. acquired a new position in shares of AC Immune in the 3rd quarter valued at approximately $142,000. Janus Henderson Group PLC bought a new position in AC Immune during the 3rd quarter worth $13,345,000. Artal Group S.A. lifted its holdings in shares of AC Immune by 25.0% in the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after buying an additional 150,000 shares during the period. Finally, FMR LLC lifted its stake in AC Immune by 28.9% in the 3rd quarter. FMR LLC now owns 5,209,673 shares of the company’s stock worth $41,678,000 after acquiring an additional 1,166,524 shares in the last quarter. 29.30% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: Investing in Blue-Chip Stocks

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.